Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on investigational drugs"
DOI: 10.1080/13543784.2023.2212154
Abstract: INTRODUCTION There are no U.S. Food and Drug Administration (FDA) approved therapies for cutaneous lupus erythematosus (CLE). Litifilimab is a monoclonal antibody against BDCA2, a plasmacytoid dendritic cell specific antigen, currently under investigation for systemic… read more here.
Keywords: cle; litifilimab; trial; lupus erythematosus ... See more keywords